IMATINIB, tablets, 100 mg and 400 mg (as mesylate), Glivec®
Page last updated: 20 October 2010
PDF printable version for IMATINIB, tablets, 100 mg and 400 mg (as mesylate), Glivec® (PDF 30 KB)
Public Summary Document
Product: IMATINIB, tablets, 100 mg and 400 mg (as
mesylate), Glivec®
Sponsor: Novartis Pharmaceuticals Australia Pty
Ltd.
Date of PBAC Consideration: July 2010
1. Purpose of Application
The submission sought an extension to the current authority
required listing for imatinib to include the adjuvant treatment for
12 months of a patient at high risk of recurrence following
complete resection of primary gastrointestinal tumour (GIST) who
meets certain criteria.
2. Background
At the November 2009 meeting, the PBAC rejected a submission for an
authority required listing for adjuvant treatment of GIST on the
basis of uncertain clinical benefit and a high and highly uncertain
cost-effectiveness ratio.
Full details in the November 2009 Public Summary
Document.
3. Registration Status
The TGA registration for imatinib was extended on 17 June 2009 to
include the adjuvant treatment of adult patients following complete
gross resection of KIT (CD117)-positive primary GIST.
4. Listing Requested and PBAC’s View
Changes to the current restriction for imatinib for metastatic and/or unresectable
GIST have been highlighted in italics and strikethrough.
NOTE:
Imatinib mesylate is not PBS-subsidised for the treatment of patients with resectable
malignant gastrointestinal stromal tumours.
Authority required
Adjuvant treatment of an adult patient at high risk of recurrence following complete
resection of primary gastrointestinal stromal tumour which has been histologically
confirmed by the detection of CD117 on immunohistochemical staining, at a dose not
exceeding 400 mg/day for a period of 12 months.
High risk of recurrence is defined as:
Primary GIST greater than 5 cm with a mitotic count of greater than 5/50 high power
fields (HPF); or
Primary GIST greater than 10 cm with any mitotic rate; or
Primary GIST with a mitotic count of greater than 10/50 HPF
(Prognosis definition based on the Australian and New Zealand consensus approach to
best practice management, see Zalcberg et al. Asia-Pacific Journal of Clinical Oncology
2008: 4.4: 188-98.)
Authority required (grandfathering)
Initial treatment of a patient who was receiving adjuvant imatinib mesylate for GIST
prior to {list date} and who meets the above PBS criteria. The patient is eligible
to receive sufficient imatinib at a dose of 400 mg/day to complete 12 months of combined
PBS-subsidised and non-PBS-subsidised therapy.
Applications for authorisation must be in writing and must include:
(1) a completed authority prescription form; and
(2) a completed Imatinib Mesylate (Glivec) PBS Authority Application for Use in Adjuvant
Treatment of Gastrointestinal Stromal Tumour - Supporting Information Form [may be
downloaded from the Medicare Australia website (www.medicareaustralia.gov.au)] which
includes the following:
(i) a copy of a pathology report from an Approved Pathology Authority supporting the
diagnosis of a gastrointestinal stromal tumour and confirming the presence of CD117
on immunohistochemical staining; and
(ii) a copy of the most recent (within 2 months of the application) computed tomography
(CT) scan, magnetic resonance imaging (MRI) or ultrasound assessment of the tumour(s),
including whether or not there is evidence of metastatic disease; and
(iii) a written statement indicating that the date of tumour resection was not more
than 3 months prior to the date of this application; and
(iv) a copy of the pathology report must include the size and mitotic rate of the
tumour
Change the NOTE in the current continuing treatment restriction for metastatic GIST
as follows:
Authority required
Continuing PBS-subsidised treatment, at a dose of up to 600 mg per day, of adult patients
with a metastatic or unresectable malignant gastrointestinal stromal tumour who have
previously been issued with an authority prescription for this drug.
NOTE:
Patients with metastatic/unresectable disease who achieve a response to treatment at an imatinib dose of 400 mg per day should
be continued at this dose and assessed for response at regular intervals. Patients
who fail to achieve a response to 400 mg per day may have their dose increased to
600 mg per day. Authority applications for doses higher than 600 mg per day will not
be approved.
For PBAC’s view, see Recommendation and Reasons.
5. Clinical Place for the Proposed Therapy
Gastrointestinal stromal tumours (GIST) are rare and occur in the
muscular layer of the digestive tract. Surgery has been the sole
treatment for primary localised GIST and most patients after
surgery are observed (‘watchful waiting’). However,
surgery alone is not curative for the majority of patients and over
50% of patients will have disease recurrence within 2 years.
Recurrence can occur as a result of tumour rupture during surgery
or after “complete” resection due to unsuspected
microscopic tumour dissemination.
It is proposed that adjuvant treatment with imatinib following
complete resection of the primary GIST would provide a treatment
option after surgery and may prevent disease recurrence in those
patients classified as being at high risk of metastatic disease
recurrence.
For PBAC’s view, see Recommendation and
Reasons.
6. Comparator
The submission nominated placebo as the main comparator.
For PBAC’s view, see Recommendation and
Reasons.
7. Clinical Trials
No changes were made to the trial data which were presented in the
November 2009 submission. The trials have been previously reported
in the November 2009 Public Summary Document.
8. Results of Trials
The key results of Trial Z9001 have been previously reported in the
November 2009 Public Summary Document.
9. Clinical Claim
The re-submission described imatinib mesylate as superior in terms
of comparative efficacy over placebo.
For PBAC’s view, see Recommendation and
Reasons.
10. Economic Analysis
The re-submission presented an updated stepped economic evaluation
based on a single cohort Markov model and included seven health
states. The outcomes generated by the modelled economic evaluation
were the incremental cost per recurrence-free year, incremental
cost per life-year gained and incremental cost per QALY gained.
Compared to the model used in the November 2009 submission, the
re-submission included the use of sunitinib treatment for patients
with progressive disease in the metastatic setting.
Based on the structure and assumptions used in the
re-submission’s model, adjuvant imatinib treatment of GIST is
associated with both an incremental cost per life year gained and
an incremental cost per QALY gained of between $45,000 and $75,000
compared with placebo and could be more than $100,000 per QALY if
no survival gain is assumed. These were higher, but within the same
range than the ICER’s generated in the previous
submission.
The PBAC noted the results of the sensitivity analyses indicated
that the model was most sensitive to; the trial-based treatment
effect (hazard ratio for recurrence-free survival), adherence rates
in the adjuvant setting, utility scores in the adjuvant health
state, disutility associated with adjuvant imatinib, baseline risk
of recurrence in different patient populations and the estimated
efficacy of metastatic imatinib in patients with prior adjuvant
exposure.
Although the re-submission had incorporated sunitinib into the
economic analysis and updated the supportive evidence, the PBAC
considered that many of the uncertainties identified with the
economic analysis in the November 2009 submission remained in the
re-submission.
For PBAC’s view, see Recommendation and Reasons.
11. Estimated PBS Usage and Financial Implications
The re-submission estimated the likely number of patients per year
to be less than 10,000 in Year 5, at a cost per year to the PBS of
less than $10 million in Year 5, lower than in the previous
submission.
If cost offsets are not included in the estimates, the financial
cost to the PBS in Year 5 of listing is higher, though still less
than $10 million.
12. Recommendation and Reasons
The PBAC noted that no new clinical data were provided and the
comparator and the clinical claim were the same as for the November
2009 submission, both of which were previously accepted by the
PBAC. The revised treatment algorithm included sunitinib as second
line treatment in the metastatic setting which was not available on
the PBS at the time of lodging the November 2009 submission.
The PBAC accepted it was reasonable to limit the eligible
population to patients at high-risk of recurrence according to the
NIH criteria as a pragmatic way forward.
However, the PBAC agreed that that the following issues remain
unresolved.
The PBAC considered that there was insufficient evidence to
determine whether adjuvant therapy prevents or delays disease
recurrence as the follow up of Study Z9001 was too short. The PBAC
noted that a minimum 3 year follow-up post imatinib data will be
available in 2011 for Study Z9001.
The PBAC acknowledged there was a clinical need for adjuvant
treatment and an improvement in overall survival is the desired
outcome for patients in the adjuvant setting. The PBAC noted that
clinical trial demonstrated significantly increased recurrence-free
survival (RFS) with imatinib compared with placebo (all risk groups
combined) (38 months versus 20 months). However, the PBAC
considered that whilst recurrence-free survival may be a useful
surrogate outcome in particular cancers (breast cancer, colorectal
cancer) which have a substantial body of evidence supporting the
use of surrogate measures in the adjuvant setting, this did not
mean that recurrence-free survival would necessarily be a valid
surrogate for overall survival in GIST patients. The PBAC agreed
that until definitive data become available in 2015, considerable
uncertainty will remain around the estimate of the comparative
treatment effect for overall survival.
The PBAC noted that although the restriction limits treatment to 12
months based on the duration of treatment in Trial Z9001, the
appropriate length of treatment is still unknown. The PBAC noted
that clinical trials were currently testing the following treatment
durations: 0 versus 1 year (Z9001), 0 versus 2 year (EORTC) and 1
versus 3 year (SSG), and comparative data with RFS as endpoint will
be available in 2013.
The PBAC noted that the economic model did not incorporate the
costs and disutility associated with adverse events. However,
adjuvant imatinib treatment is associated with a higher frequency
of serious adverse events and dose reduction and/or discontinued
therapy due to adverse events compared to placebo. The model also
assumed that adjuvant imatinib treatment did not affect the
effectiveness of imatinib in the metastatic setting (i.e. there is
no imatinib resistance). However, there was uncertainty regarding
whether use in the adjuvant setting modifies the treatment effect
of imatinib in the metastatic setting. The PBAC noted that the
clinical trials indicated that imatinib is effective in previously
exposed patients, but there was uncertainty about whether the
effect is equivalent to that seen in naïve patients. The PBAC
agreed that the model is highly sensitive to estimated efficacy of
imatinib in the metastatic setting.
The PBAC noted that the economic model assumed that the delay in
disease recurrence translated directly into an increase in survival
despite no trial data to support an overall survival benefit with
adjuvant imatinib, nor data to support recurrence-free survival as
a valid surrogate for overall survival in the adjuvant setting in
GIST. The PBAC agreed that the main gains in quality-adjusted life
years (QALYs) in the model are related to gains in life years not
gains in quality of life, despite no validated evidence
demonstrating a survival benefit.
Based on the structure and assumptions used in the
re-submission’s model, adjuvant imatinib treatment of GIST is
associated with an incremental cost per life year gained and an
incremental cost per QALY gained of between $45,000 and $75,000
compared with placebo (correcting for errors in the calculation of
costs for sunitinib and non-drug costs in the adjuvant setting) and
could be more than $100,000 per QALY if no survival gain is
assumed. The PBAC noted that the cost-effectiveness ratios are
disproportionally higher than cost-effectiveness ratios accepted in
other adjuvant settings such colorectal and breast cancer.
The PBAC therefore rejected the submission on the basis of
uncertain clinical benefit and an unacceptably high and uncertain
cost-effectiveness ratio.
The PBAC noted that whilst the Managed Entry proposal might address
the clinical uncertainty, the ICER remains unacceptably high at the
price proposed by the sponsor. The PBAC also noted that the
earliest starting date of any Managed Entry Scheme is 1 January
2011 as agreed with Medicines Australia in the Memorandum of
Understanding.
The PBAC noted that the submission meets the criteria for an
independent review.
Recommendation:
Reject
13. Context for Decision
The PBAC helps decide whether and, if so, how medicines should be
subsidised in Australia. It considers submissions in this context.
A PBAC decision not to recommend listing or not to recommend
changing a listing does not represent a final PBAC view about the
merits of the medicine. A company can resubmit to the PBAC or seek
independent review of the PBAC decision.
14. Sponsor’s Comment
Novartis Pharmaceuticals Australia welcomes the PBAC’s
acknowledgement of the clinical need for Glivec® for
adjuvant treatment of GIST and will continue to work with the PBAC
to make Glivec® available under the PBS for this
patient group.